Q-Immune, Inc. filed a Form D with the Securities and Exchange Commission on 2026-09-28.
Q-Immune, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 28, 2026. The filing reports $25K sold. Its industry group is Biotechnology. It names Cameron McCann (Executive Officer, Director, Promoter), Stephen Paucha Smith (Executive Officer, Director) (SEC Form D, September 28, 2026).
Sell to companies like Q-Immune, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-28 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Q-Immune, Inc.
Free to see. No signup.
More on the people and the money behind Q-Immune, Inc., from the filings we hold.
Biotechnology raises by companies based in Washington, filed within 90 days of this one, largest first.
Get an email when Q-Immune, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Q-Immune, Inc. raises, hires or launches. No email unless you switch it on.
Watch Q-Immune, Inc. →Get the full cited report on Q-Immune, Inc.
What the filing shows about Q-Immune, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Q-Immune, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $25K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
Q-Immune provides cutting-edge real-time protein network analysis for CAR-T cells, enabling accurate efficacy prediction, optimized CAR-T design, and improved immunotherapy outcomes to advance patient treatment strategies.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Cameron McCann is named as Executive Officer and Director and Promoter on the Form D that Q-Immune, Inc. filed with the SEC on 28 September 2026, one of 2 people that filing names.
Stephen Paucha Smith is named as Executive Officer and Director on the Form D that Q-Immune, Inc. filed with the SEC on 28 September 2026, one of 2 people that filing names.
2 people named on the filing — 2 holding an executive role.
Named as of the 2026-09-28 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
What the filing shows about Q-Immune, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Q-Immune, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Q-Immune, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Q-Immune, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Q-Immune, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-30 (qimmune.com).
Each opens in a new tab, filled in for Q-Immune, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises, week of 2026-09-28 · Biotech raises in Seattle
https://mentionfox.com/funding/q-immune-inc-form-d-000001